Previsión
El precio objetivo medio de los analistas es de 7,59 € (+0,93 %). La mediana es de 7,29 € (-3,06 %).
| Comprar |
6 |
| Mantener |
0 |
| Vender |
0 |
Debates en la comunidad
Todavía no hay ninguna discusión sobre este activo.
Iniciar debateNoticias Ir al feed de noticias
DiaMedica Q2 loss in line with guidance; clinical programs make progress
DiaMedica reported an adjusted loss of $0.19 per share in the second quarter, exactly matching consensus, and no revenue. The biotech company observed significant blood pressure effects in the late preeclampsia study, completed the first cohort in the early fetal growth restriction trial, and has recruited over 85% of patients for the ReMEDy2 stroke interim analysis. Cash and equivalents amounted to $43.5 million as of June 30, which management says should fund operations and studies through 2027, while R&D expenses rose markedly. The stock reacted positively in premarket trading; near‑term milestones include further cohort recruitment, top‑line data and steps toward a U.S. IND submission. » Más en de.investing.com
1 Main Capital highlights DiaMedica Therapeutics for DM199 stroke‑recovery potential
1 Main Capital said it holds an opportunistic position in DiaMedica Therapeutics, citing DM199, a recombinant form of tissue kallikrein‑1 (KLK1), as a promising therapy for ischemic stroke recovery. The fund noted extensive real‑world use of naturally derived KLK1 in China and positive signals from pooled and Phase 4 studies, while acknowledging those data are not FDA‑caliber and DM199 is not identical to the Chinese product. DiaMedica closed at $6.34 on July 31, 2026, with a market cap near $342 million and mixed recent returns. » Más en finance.yahoo.com
DiaMedica Therapeutics strengthens liquidity and reports slightly better EPS for Q4 2025
DiaMedica Therapeutics reported Q4 2025 EPS of -$0.17, slightly above expectations, and increased cash and equivalents to $59.9 million (+35.8%). Operating cash outflow rose due to higher R&D spending, including the expansion of the ReMEDy2 study. Management expects current liquidity to fund operations through the end of 2027; the stock fell 2.21% in after-hours trading. » Más en de.investing.com
DiaMedica receives Health Canada approval for phase-2 study of DM199 in early-onset preeclampsia
DiaMedica has received a 'No Objection Letter' from Health Canada to start an open-label phase-2 dose-finding study of DM199 in early-onset preeclampsia. The study, planned for 2026, will test three dose levels, administer DM199 subcutaneously every three days until delivery, and assess safety, tolerability and exploratory efficacy markers such as pulsatility index, sFlt‑1 and placental growth factor. The company plans to expand the study to the US and the UK after regulatory clearances. According to the data, DiaMedica shows high short-term liquidity; analysts have price targets between $11 and $25, while InvestingPro currently considers the stock overvalued. » Más en de.investing.com
DiaMedica must conduct additional non-clinical study for DM199 after FDA talks
The FDA requires, before an IND filing for treatment of early-onset preeclampsia, a 10-day modified embryo‑fetal plus pre- and postnatal study in rabbits, with results expected by Q2 2026. DiaMedica announced it will carry out this study for its drug DM199 (Rinvecalinas‑Alfa) and said the talks provided regulatory clarity on the non-clinical data package. At the same time, an investigator-initiated phase‑2 trial in South Africa is already treating more than 30 women with late-stage preeclampsia; preliminary data show encouraging safety and efficacy signals. Analysts have lowered their earnings estimates following the news, and the stock has recently fallen. » Más en de.investing.com
Dividendos históricos Dividendos
Todas las métricas de dividendos Todas las métricasEn 2022, DIAMEDICA THERAPEUT. ya ha pagado 2,74 € en dividendos. El último pago fue en marzo de 2022.
Datos financieros
En el último trimestre, DIAMEDICA THERAPEUT. tuvo unos ingresos de 0 € y un beneficio neto de -9,99 M €
| (EUR) | septiembre de 2026 | YoY |
|---|---|---|
| Ingresos | 0 | - |
| Beneficio bruto | 0 | - |
| Beneficio neto | -9,99 M | 35,94 % |
| EBITDA | -9,97 M | 36,08 % |
Datos fundamentales
| Métrica | Valor |
|---|---|
Capitalización bursátil | 405,69 M € |
Número de acciones | 53,96 M |
Máximo/mínimo de 52 semanas | 10,02 € - 4,78 € |
| Dividendos | No |
Beta | 0,94 |
Ratio P/E | -10,86 |
Ratio PEG | 1,57 |
Ratio P/B | 15,53 |
Ratio P/S | 0,00 |
Perfil de la empresa
DiaMedica Therapeutics Inc., una empresa biofarmacéutica en fase clínica, desarrolla tratamientos para enfermedades neurológicas y renales. El principal candidato a fármaco de la compañía es DM199, una proteína recombinante de calicreína-1 tisular humana, que se encuentra en el ensayo REDUX de fase 2 para el tratamiento de pacientes con enfermedad renal crónica moderada o grave causada por diabetes tipo I o tipo II; y en los ensayos REMEDY2 de fase 2/3 para el tratamiento de pacientes con ictus isquémico agudo. También desarrolla DM300, que se encuentra en fase preclínica para el tratamiento de enfermedades inflamatorias. La empresa era conocida anteriormente como DiaMedica Inc. y cambió su nombre a DiaMedica Therapeutics Inc. en diciembre de 2016. DiaMedica Therapeutics Inc. se constituyó en 2000 y tiene su sede en Minneapolis, Minnesota.
| Nombre | DIAMEDICA THERAPEUT. |
| CEO | Dietrich John Pauls |
| Sede | Minneapolis,
mn Estados Unidos |
| Sitio web | |
| Sector | Materiales |
| Industria | Productos químicos |
| Salida a bolsa | 03/08/2012 |
| Empleados | 35 |
Símbolos bursátiles
| Bolsa | Símbolo |
|---|---|
NASDAQ | DMAC |